Recently, impressive progress has been made in understanding the etiology and pathophysiological mechanisms involved in renal diseases in pediatric patients. Research shows that current treatment methods can be useful if they are applied to the early stages of the disease and sensitive early biomarkers are identified. In this regard, an important role would be played by the evaluation of serum paraoxonase family proteins at the onset and clinical-evolutionary stages of the pathology. Purpose of the study: Highlighting the pathogenetic role of PON family proteins in the diagnosis, treatment, medical and surgical resolution of children with congenital reno-urinary anomalies (CRUA). Material and methods: The serum level of paraoxonase family proteins (PON) was evaluated in 60 patients aged 0-18 years with CRUA, including 20 – with congenital hydronephrosis (HN), 20 – with vesicoureteral reflux (VUR) and 20 – with megaureterohydronephrosis (MUH). The comparison group (control) consisted of 20 practically healthy children of the same age. The laboratory examination included the evaluation of specially selected serum biomarkers – the level of PON family proteins (PON phenylacetate and PON pNitroFA). Results: The number of children with ACRU has been shown to increase in recent decades, while the serum level of PON proteins (PON phenylacetate and PON pNitroFA) has shown a tendency to decrease compared to the control group. Conclusions: The data obtained reveal the informativeness and high value of estimating the serum level of PON family proteins and which can be used as sensitive biomarkers, valuable in assessing the activity of the inflammatory process but also the effectiveness of the applied treatment.
Bernic et al. (Wed,) studied this question.